Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Immunotherapy

Rewiring cancer cells

Nature Reviews Cancer volume 17, pages 706–707 (2017)Cite this article

Subjects

A number of factors ranging from the scarcity of tumour-specific neoantigens, tumour immunosuppression and toxicity caused by systemic delivery of immunomodulators restrict the efficiency of cancer immunotherapies. To overcome these obstacles, Nissim, Wu et al. have engineered a synthetic gene circuit enabling the production of combinatorial immunomodulators specifically from within cancer cells to trigger an antitumour T cell response.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Get just this article for as long as you need it

$39.95

Learn more

Prices may be subject to local taxes which are calculated during checkout

References

  1. Nissim, L., Wu, M. R. et al. Synthetic RNA-based immunomodulatory gene circuits for cancer immunotherapy. Cell http://dx.doi.org/10.1016/j.cell.2017.09.049 (2017)

Download references

Authors
  1. Anna Dart
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Dart, A. Rewiring cancer cells. Nat Rev Cancer 17, 706–707 (2017). https://doi.org/10.1038/nrc.2017.112

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrc.2017.112

Search

Advanced search

Quick links

Nature Briefing: Cancer

Sign up for the Nature Briefing: Cancer newsletter — what matters in cancer research, free to your inbox weekly.

Get what matters in cancer research, free to your inbox weekly. Sign up for Nature Briefing: Cancer